LiquidHALLMARK® is a sensitive next-generation sequencing assay targeting both circulating DNA and RNA to profile a patient’s unique cancer. With a blood draw, LiquidHALLMARK provides important information for cancer care especially when tissue by invasive biopsy is insufficient or inaccessible
LiquidHALLMARK profiles ctDNA mutations in 80 genes, fusions in 10 genes, and somatic variants. As an add-on option, LiquidHALLMARK analyses 27 ctRNA targets for actionable and emerging fusions. LiquidHALLMARK targets genes that are commonly associated with 15 cancers, including lung, breast and colon cancer.
At 0.1% limit of detection (LOD) for single nucleotide variants (SNVs) and insertion–deletion mutations (indels), LiquidHALLMARK identifies more actionable mutations allowing physicians to make informed decisions to guide care across the whole patient journey – from diagnosis and initial therapy selection, monitoring of therapy response, to the detection of emergent mutations that drive disease burden over time.
Just one draw
Quick turnaround
0.1% Limit of Detection of MAF
To enable better clinical decisions, we offer comprehensive genomic profiling of clinically relevant cancer mutations and biomarkers across several tumor types. With our wide array of tests, Physicians can select the one that is best suited to a patient’s unique cancer and clinical history.
LiquidHALLMARK is our flagship next-generation sequencing test for genomic profiling of solid tumors. Through a non-invasive blood draw, personalised patient results are delivered in 14 working days. LiquidHALLMARK provides important information for cancer care especially when tissue by invasive biopsy is insufficient or inaccessible.
| 80 genes | 10 fusions | MSI | 3 Viruses |
LiquidHALLMARK can detect a wide range of mutation types-single nucleotide variants (including cis-trans), short insertions and deletions (indels), copy number variants (CNVs), microsatellite instability (MSI), and fusions. LiquidHALLMARK targets 80 genes that are commonly associated with 15 major cancers including lung, breast, and colon.
Tissue500™ is a comprehensive genomic profiling test that detects clinically relevant mutations in 572 genes to identify a patient’s unique cancer signature.
| 572 genes | 71 fusions | MSI | TMB |
Tissue500 can detect multiple classes of genomic alterations -single nucleotide variants, short insertions and deletions (indels), copy number variations (CNVs), microsatellite instability (MSI) status and tumor mutational burden (TMB) in solid tumors.
Complete the test order / requisition form
Collect Blood Sample and label tubes with 2 patient-specific identifiers
Place blood tubes into paper sleeves and biohazard bag, and finally into the kit box
Cover the biohazard bag with gel pack provided
Include test order form and any other relevant forms
Use the courier forms in the kit to send the sample to us
BMG LAB SERVICES is ready to take care of you.
Copyright © 2022 by Bangkok Molecular Genetics. All Rights Reserved.